A one-stage, needle-delivered surgical technique study
MSK DoctorsNanoACi 100
The treatment phase of NanoACi 100 is complete and the series is now in its observation stage. Professor Paul Lee reports encouraging early findings, with a four-point reduction in pain on the 0–10 visual analogue scale (VAS) at six-week follow-up. Analysis and follow-up are ongoing.
Part of the MSK injection therapies observational cohort study · REC 26/SW/0096 · IRAS 375544.
100
Treatments complete
Observation
Current stage
6 weeks
Pain follow-up
The Clinical Imperative
Can cartilage treatment become simpler without losing scientific rigour?
Articular cartilage has limited intrinsic healing capacity. Established autologous chondrocyte implantation pathways can involve arthroscopic harvest, laboratory expansion and a later implantation procedure. NanoACi is designed as a one-stage surgical alternative; NanoACi 100 assesses clinical outcomes following treatment.
Traditional cultured-cell ACI
- Arthroscopic cartilage harvest
- Cell culture and laboratory expansion
- Later implantation procedure
- Longer, multi-stage treatment pathway
NanoACi
- Small auricular cartilage harvest
- Point-of-care mechanical preparation
- No cell culture or enzyme digestion
- Needle delivery during one surgical session
Research question
Is the NanoACi technique safe, reproducible and associated with meaningful improvement in pain, function and imaging measures?
The Surgical Technique
One session. Three autologous components.
NanoACi is being studied as a tissue-harvesting, preparation and reimplantation procedure — not simply as an injection. Under local anaesthetic, small cartilage and perichondrial samples are harvested from the auricular concha. The tissue is mechanically prepared at the point of care into micrografts, combined with an in-situ-forming collagen scaffold and platelet-rich plasma (PRP), then implanted by ultrasound-guided needle delivery.
Protocol principle: autologous, mechanically prepared, non-arthroscopic and completed without laboratory cell expansion.
Harvest
Auricular cartilage and perichondrium
Prepare
Point-of-care mechanical micrografts
Combine
Collagen scaffold and autologous PRP
Implant
Ultrasound-guided needle delivery
Study Design
Clinical outcomes in the NanoACi 100 series.
The treatment phase of NanoACi 100 is complete and the series is now in its observation stage. Professor Paul Lee reports encouraging early findings, with a four-point reduction in pain on the 0–10 visual analogue scale (VAS) at six-week follow-up. Analysis and follow-up are ongoing. Its purpose is to characterise delivery of the technique, establish an early safety profile and measure clinical and functional change over time.
100
Treatments complete
1
Standardised technique
6
Assessment points
24m
Planned observation
Population
Adults with symptomatic knee cartilage disease or osteoarthritis selected through whole-joint clinical assessment.
Primary evaluation
Change in Motion Age from baseline to 12 months, alongside systematic procedural and safety reporting.
Secondary evaluation
VAS pain, OKS, patient experience, individual movement biomarkers, MRI findings and further intervention.
Outcome Framework
Measuring what changes — and what matters.
The evaluation combines patient-reported experience, objective movement analysis, safety surveillance and structural imaging. NanoACi 100 analysis and follow-up are ongoing.
Motion Age
Markerless movement analysis will quantify functional change, including sit-to-stand, squat and related movement biomarkers.
Pain & patient experience
VAS pain, Oxford Knee Score (OKS), global improvement and satisfaction will describe the patient-reported response.
Safety
Complications, inflammatory reaction, infection, donor-site events, unplanned admission and further intervention will be recorded.
MRI
Planned imaging review will assess cartilage thickness and repair morphology at defined follow-up points.
Functional Biomarker · Motion Age
Motion Age turns movement into an understandable functional measure.
Beyond questionnaires: markerless video analysis examines how a person moves and compares that pattern with age-related movement benchmarks.
For NanoACi 100, Motion Age will provide an objective complement to pain scores and patient-reported outcomes, helping the study detect whether movement quality changes after the procedure.
Planned Follow-Up
From baseline to two years.
- 0
Baseline
Clinical, patient-reported, Motion Age and imaging assessment
- 6w
Early review
Recovery, safety and rehabilitation progress
- 3m
Initial response
Pain, function and adverse events
- 6m
Functional review
Patient outcomes and Motion Age
- 12m
Primary analysis
Full outcome set, Motion Age and MRI
- 24m
Durability
Longer-term clinical and imaging follow-up
NanoACi 100
Prospective evaluation of a needle-delivered, one-stage autologous chondrogenic surgical technique for knee cartilage disease.
Background
Cartilage has limited healing capacity, while established autologous chondrocyte implantation can require tissue harvest, cell culture and a later implantation procedure. NanoACi is a minimally invasive, surgeon-led technique combining auricular cartilage micrografts, a collagen scaffold and platelet-rich plasma during one treatment session.
Methods
NanoACi 100 examines clinical outcomes following NanoACi treatment in adults with symptomatic knee cartilage disease or osteoarthritis. Following whole-joint assessment, auricular cartilage and perichondrium will be mechanically prepared at the point of care, combined with collagen scaffold and PRP, and implanted under ultrasound guidance. Assessments are planned at baseline, 6 weeks, 3, 6, 12 and 24 months.
Observation stage
The study will characterise procedural safety and reproducibility and examine change in Motion Age, VAS pain, OKS, patient experience, movement biomarkers and MRI features. Further treatment and progression to knee arthroplasty will also be recorded. The treatment phase of NanoACi 100 is complete and the series is now in its observation stage. Professor Paul Lee reports encouraging early findings, with a four-point reduction in pain on the 0–10 visual analogue scale (VAS) at six-week follow-up. Analysis and follow-up are ongoing.
Conclusion
With the treatment phase complete, NanoACi 100 now follows every patient through the planned observation points. The early clinical update describes pain at six weeks; continued follow-up will assess function, imaging and the course of recovery.
The Road Ahead
Evidence built in deliberate stages.
Now
Technique evaluation
Treatment phase complete. The consecutive series is now being observed for delivery, safety and clinical signal.
Next
External validation
Replicate findings across surgeons, settings and clearly defined patient groups.
Then
Comparative assessment
Evaluate NanoACi against appropriate established treatments in a controlled design.
Final study registration, eligibility criteria and analysis plan will follow completion of research governance and protocol approvals.
Funding and affiliations
Affiliations: Affiliations as stated in the publication.